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Introduction
Urinary bladder cancer (BCa) accounts for about 7% of all 
new cancers in the United States with 81,190 estimated new 
cases and 17,240 deaths in 2018 (1). Of all patients with 
BCa, approximately 75% will be diagnosed with a non-
muscle-invasive BCa (NMIBC) (2) affected by an average 
recurrence and progression rates of 60–80% and 10–30%, 
respectively (3). As a direct consequence of the high 
recurrence and progression rates, NMIBC accounts for the 
highest lifetime treatment cost per patient of all cancers (4). 
Depending on the country, BCa costs from diagnosis-to-
death between $89,287 and $202,203 per person and it will 
likely increase as survival rates increase. Costly surveillance 
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and treatment of BCa can lead to financial toxicity, defined 
as treatment-related financial distress, with an estimated 
rate of 24% (5).
Optimization of treatment and surveillance intervals 
is pivotal to reduce recurrence and progression and to 
optimize costs. The risk estimation of harboring recurrence 
or progression depends on multiple factors and several 
classifications have been proposed to stratify patients, such as 
EORTC Genito-Urinary Cancer Group scoring system (6) 
and CUETO risk calculators (7). 
Intravesical chemotherapeutical agents after transurethral 
resection (TURB) have shown to be effective on reducing 
the risk of recurrence and progression during the 
follow up (8). Specifically, an early single chemotherapeutical 
instillation (SI) might play a role for certain patients. On 
the other hand, the efficacy of this treatment has been 
questioned and many urologist are reluctant to its use (9,10). 
For all these reasons, we sought to review and summarize 
the current evidence regarding the possible impact on 
recurrence and progression of SI.
Evidence acquisition
A non-systematic Medline/PubMed literature search was 
performed with different combination of terms as “bladder 
cancer”, “early instillation”, “single instillation”, “Immediate 
instillation”, “chemotherapy”, “TURB”, “Epirubicin”, 
“Mitomycin” and “non-muscle invasive bladder cancer”. 
Only articles in English language were retained for the 
review. Time period included articles between 1988 and 
2018. Meta-analyses and original articles on randomized 
controlled trials comparing a single instillation of 
chemotherapy after TURB and TURB alone or TURB plus 
placebo or TURB with delayed instillation with endpoints 
recurrence and progression rate were selected and assessed 
from authors’ bibliographies.
Overview of the management of NMIBC and risk 
grouping
Most of  newly diagnosed cases  of  BCa require a 
conservative management (2). The final decision on 
subsequent diagnostic/therapeutic process is usually 
based upon specimen obtained at TURB. To optimize 
treatment, patients could be stratified in risk classes to 
predict separately short- and long-term recurrence and 
progression risk. Patients are stratified in 3 risks group 
(low, intermediate and high) based on several pathological 
and clinical features with some differences among available 
guidelines: EAU (European Association of Urology) (2), 
National Institute for Health and Care Excellence (NICE), 
Canadian Urological Association (CUA) (11) and American 
Association of Urology (AUA) (12) incorporate this strategy 
into their guidelines whereas National Comprehensive 
Cancer Network (NCCN) (13) does not. All guidelines 
recommend SI for certain categories of patients. Figure 1 
illustrates a flow chart with summary data regarding the 
therapeutical management of BCa after TURB.
EAU guidelines (2) recommend intravesical single 
instillation for all patients with low risk tumors [according 
to EORTC score (6)] after a complete TURB. Instead, 
for patients with intermediate risk, one-year full dose 
BCG treatment or instillations of chemotherapy should 
be provided with the addition of one SI in patients with 
previous recurrence rate ≤1 per year and expected EORTC 
recurrence score <5. In the AUA guidelines (12) SI is 
suggested for patients with suspected or known low- or 
intermediate-risk BCa whereas CUA (11) and NICE 
guidelines recommends SI in all patients with a suspected 
NMIBC. In all guidelines except for NICE it is underlined 
that SI should not be administered in extended resections or 
in suspicion of bladder perforation. 
The effect of single postoperative instillation 
after TUR
Table 1 illustrates a selection of randomized control trials 
testing the impact of SI on recurrence and progression 
rates. In the last 15 years, several meta-analyses were 
published testing the effect of SI in BCa patients treated 
with TURB. Sylvester et al. (30) analyzed in 2004, 1,476 
patients affected by TaT1 single and multiple BCa with 
a median follow up of 3.4 years. Patients treated with SI 
recorded a decrease of 39% recurrence risk [odds ratio 
(OR) 0.61, confidence interval (CI): 0.49–0.75, P<0.0001]. 
The effect was similar between trials using epirubicin, 
mitomycin C and pirarubicin whereas no benefit was 
observed using thiotepa. Abern et al. (31) analyzed data 
from 18 randomized trials with a total of 3,103 patients 
reporting an absolute reduction of 13% in recurrence 
for patients who received immediate SI. Perlis et al. (32) 
in a meta-analysis published in 2013 found a prolonged 
recurrence free interval for patients treated with SI by 38% 
(HR: 0.62, 95% CI: 0.50–0.77; P<0.001) (32). The most 
recent meta-analysis was performed on individual patients’ 
data (n=2,278) obtained from 11 randomized studies 
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comparing TURB with TURB plus SI. The difference in 
time of first recurrence between treatments was statistically 
significant in favor of single instillation, with a reduction of 
35% in relative risk of recurrence [hazard ratio (HR): 0.65, 
95% CI: 0.58–0.74, P<0.001]. The 5-years recurrence rates 
were 44.8% (95% CI: 41.6–48.0%) on a single instillation 
and 58.8% (95% CI: 55.7–61.9%) on TURB (33). The last 
randomized trial (29) published in the literature compared 
patients who underwent immediate single instillation 
(given within <24 h) with Mitomycin C versus delayed 
instillation (2 weeks after TURB). At 3 years of follow up, 
there was a recurrence risk of 27% (95% CI: 24–30%) in 
the immediate group versus 35% (95% CI: 33–39%) for 
the delayed group with a 34% of relative risk reduction on 
recurrence (HR: 0.66, 95% CI: 0.56–0.79, P<0.001) (29). 
To summarize,  results  of  randomized control led 
trials and meta-analysis strongly support that SI of 
chemotherapeutical agent reduces recurrence in NMIBC, 
with about 35% of relative reduction rates. Theories 
explaining this effect include the prevention of implantation 
of floating cells into the bladder urothelium following 
resection (34-36), and the ablative effect on residual tumor 
cells at the tumor site and on small unnoticed tumors left 
behind TURB. It should be emphasized that in the majority 
of the studies included in this review, patients were strictly 
selected including only low grade and stage tumors. Few 
data exist regarding high-risk BCa patients. Bosschieter 
et al. (29) in a sub-analysis, considered patients based upon 
their risk group and report a benefit of SI even in the high-
risk subgroup (at 3 years of follow up recurrence rates were 
for SI vs. delayed instillation, 28% vs. 35%, P=0.007).
Some authors analyzed the impact of SI on the bases of 
tumor characteristics, such as size and numbers of tumors. 
Berrum-Svennung et al. (25) reported that only patients 
with tumors <5 mm might benefit from SI in reducing 
recurrence whereas no differences were found in tumors 
>5 mm. Gudjónsson et al. (26) reported no recurrence 
rates benefit for SI in patients with multiple and recurrent 
tumors; these results were corroborated by a meta-analyses 
published in 2004 (30). In the last meta-analysis published 
by Sylvester et al. (33) a subgroup of patients (those with 
multiple tumors, tumors ≥3 cm, T1 or high recurrent 
tumors) did not benefit from SI and this indication was 
included in the EAU and AUA guidelines (2,12,33). 
Considering these results, patients with single, <3 cm and 
low-intermediate stage and grade seem most suitable to 
Figure 1 Flow chart of usage of SI in primary/recurrent BCG-naive tumors and recurrent tumor after BCG. TURB, transurethral resection 
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benefit from SI after TURB with about 35% of relative 
reduction rates. 
Timing of postoperative instillation
The EAU guidelines state that the preferred time window 
for an immediate instillation is within 2 hour after TURB.
Some discordance exists in the current guidelines 
regarding the best timing for postoperative instillations. 
EAU Guidelines state that the preferred time-window for 
an immediate instillation is within 2 hour after TURB (2). 
This recommendation is based on the last meta-analysis 
published where a non-randomized comparison suggests 
that the instillation should be more effective when given 
within 2 hours after surgery (33). CUA panel (11) suggest 
that the optimal timeframe is within 6 and 24 h whereas 
AUA guidelines proposes to administer the drug within 
24 hours after TURB (12). Despite many randomized 
controlled trials have adopted the policy of giving early 
instillations immediately or within 6–24 h after TURB, 
there are only a few randomized studies that have analyzed 
the impact of timing of SI on BCa recurrence. In addition 
to Sylvester et al. (33), Hendricksen et al. (37) did not find 
benefit in recurrence rates when SI was given the day after 
TURB whereas SI was effective when SI was given on the 
same day as TURB. On the contrary Gudjónsson et al. (26) 
found a benefit in recurrence free-survival both in patients 
in which SI was administered the same day of TURB and 
in patients in which SI was given the day after TURB 
(within 24 hours). The same results were observed in a 
recent sub-analyses obtained from a prospective multicenter 
randomized trial published in 2018 which evaluated 
differences between early instillation of mitomycin C 
administrated within 24 h after TURB on the day of TURB 
(very early instillation) and administration within 24 h 1 day 
after TURB (early instillation) (29). More studies required 
to elucidate the real optimal timing of early instillation.
Drugs in postoperative instillation
Several drugs have been administered in randomized 
controlled trials testing the effect of SI on recurrence and 
progression after TURB. Gemcitabine was tested by Böhle 
et al. (27) without finding any difference in recurrence 
rates between treatment group and placebo. These results 
were confirmed in Abern et al. (31) meta-analysis. Studies 
analyzing thiotepa and peplomycin did not reveal beneficial 
effects regarding recurrence, in contrast to pirarubicin 
that was tested by Okamura et al. (22) observing significant 
improvement of recurrence rates when compared to TURB 
alone. Mitomycin and epirubicin remain at the moment the 
mostly widely tested drugs for SI with significant advantages 
on recurrence rates (14,15,18-21,23-26,28,29). Their 
efficacy was also confirmed by Perlis et al. (32) and Sylvester 
et al. (33) meta-analysis. For these reasons, the majority of 
guidelines suggest the use of one of these two drugs for SI. 
However, at the time, there is no randomized controlled 
trial comparing the type of drug on the efficacy of SI in 
preventing recurrence or progression. 
Adverse events after single instillation
None of the analyzed randomized trial showed (Table 1) severe 
adverse events. The most common side effects included 
chemical cystitis and skin irritation. For both these adverse 
event incidences were generally low, but rates also depend 
on the type of drug used and its dosage. Chemical cystitis 
occurred with a very low incidence (0.7%) in patients treated 
with mitomycin by Tolley et al. (14) whereas rates were higher 
in a publication of De Nunzio et al. (28) (about 9%) and 
Bosschieter et al. (29) (about 5%). About 11.7% of patients 
treated with epirubicin 80 mg by Oosterlinck et al. (15) 
developed chemical cystitis. Despite the relatively high dose 
of epirubicin (100 mg) administrated by Rajala et al. (21) 
no considerable side effects were found. Solsona et al. (20) 
reported that 3.5% of patients treated with mitomycin 
developed chemical cystitis and allergic skin reaction. In 
Bosschieter et al. (29) analysis, the most reported adverse 
event in SI with mitomycin was exanthema (5.4%)
No patient treated with SI of Peplomycin 80 mg 
developed side effect (16) whereas about 2.5% of patients 
treated with SI of Thiotepa 30 mg developed chemical 
cystitis (17). Böhle et al. (27) found that adverse events 
possibly related to instillation with gemcitabine treatment 
were rare (6.6% of patients treated with gemcitabine, all 
non-serious). 
Although all of these trials showed a beneficial safety 
profile of intravesical SI a few case reports of severe 
complication are reported in literature. Nieuwenhuijzen 
et al. (38) reported a case of extravasation of mitomycin 
after instillation, resulting in severe continuous pelvic pain 
that required surgical debridement. Oddens et al. (39) 
reported three cases of severe complications: extravasation 
(which has been treated with prolonged catheterization, 
antibiotics and analgesics), abdominal pain (associated with 
a CT scan positive for an infiltrate mass between abdomen 
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and abdominal wall without sign of collection treated 
conservatively) and a paralytic ileus. For all these reasons, it 
is strongly recommended to omit SI in any case of overt or 
suspected bladder perforation or bleeding requiring bladder 
irrigation. 
Conclusions
Randomized controlled trials and meta-analyses strongly 
support the use of SI after TURB in preventing recurrence 
in low and intermediate risk patients. This effect is 
mainly evident in small (<3 cm) and solitary tumors with 
a recurrence reduction of 35%. No randomized trials 
compared the effect of different type of drugs on recurrence, 
although epirubicin or mitomycin C seems associated 
with an improved recurrence effect. It is advisable to 
administer SI within 24 h from TURB, even if the optimal 
timeframe has not yet been established. Although is a safe 
procedure, SI should not be administered in patients who 
underwent extended resections or if bladder perforation is 
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